1. Home
  2. WPP vs MIRM Comparison

WPP vs MIRM Comparison

Compare WPP & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WPP plc

WPP

WPP plc

HOLD

Current Price

$22.38

Market Cap

5.1B

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$78.82

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WPP
MIRM
Founded
1985
2018
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1B
4.2B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
WPP
MIRM
Price
$22.38
$78.82
Analyst Decision
Sell
Strong Buy
Analyst Count
1
11
Target Price
N/A
$92.45
AVG Volume (30 Days)
572.9K
813.7K
Earning Date
08-07-2025
11-04-2025
Dividend Yield
9.44%
N/A
EPS Growth
86.47
N/A
EPS
0.47
N/A
Revenue
$19,423,208,660.00
$471,794,000.00
Revenue This Year
N/A
$53.78
Revenue Next Year
N/A
$19.91
P/E Ratio
$9.08
N/A
Revenue Growth
N/A
53.66
52 Week Low
$17.47
$36.88
52 Week High
$52.26
$82.58

Technical Indicators

Market Signals
Indicator
WPP
MIRM
Relative Strength Index (RSI) 61.40 62.89
Support Level $21.93 $63.23
Resistance Level $22.28 $82.58
Average True Range (ATR) 0.44 3.74
MACD 0.14 1.62
Stochastic Oscillator 86.22 81.03

Price Performance

Historical Comparison
WPP
MIRM

About WPP WPP plc

Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: